Glutamate receptor antagonists for neuroleptic malignant syndrome and akitetic hyperthermic Parkinsonian crisis

@article{Kornhuber1993GlutamateRA,
  title={Glutamate receptor antagonists for neuroleptic malignant syndrome and akitetic hyperthermic Parkinsonian crisis},
  author={J. Kornhuber and M. Weller and P. Riederer},
  journal={Journal of Neural Transmission - Parkinson's Disease and Dementia Section},
  year={1993},
  volume={6},
  pages={63-72}
}
SummarySchizophrenia and Parkinson's disease have been considered inversely related neuropsychiatric disorders since the former has been attributed to increased dopaminergic transmission while the latter is thought to result from loss of dopaminergic neurons. It is in line with this concept that the classical neuroleptic (anti-schizophrenic) drugs cause as a side effect a drug-induced type of Parkinsonism. Most etiopathogenetic models hold that the “neuroleptic malignant syndrome” may result… Expand
43 Citations
Dopamine/glutamate interactions in Parkinson's disease
Neuroleptic malignant syndrome and serotonin syndrome.
Neuroleptic malignant-like syndrome after abrupt withdrawal of baclofen
Glutamate-based magnetic resonance spectroscopy in neuroleptic malignant syndrome
Modulation of Human Motor Cortex Excitability by Single Doses of Amantadine
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 75 REFERENCES
Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs.
Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease
Neuroleptic malignant syndrome
Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine
Neuroleptic malignant syndrome treated with subcutaneous lisuride infusion
Chronic s.c. lisuride in Parkinson's disease--motor-performance and avoidance of psychiatric side effects.
...
1
2
3
4
5
...